Trial Profile

A Pilot Study of Single-Dose Camrelizumab and/or Microwave Ablation in Women With Early-Stage Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary)
Indications Early breast cancer
Focus Adverse reactions

Most Recent Events

03 Jan 2024 Status changed from recruiting to completed.
09 Dec 2023 Results assessing safety and feasibility of camrelizumab combined with MWA in the treatment of early-stage breast cancer preoperatively, presented at the 46th Annual San Antonio Breast Cancer Symposium
19 Jul 2022 Planned primary completion date changed from 30 May 2022 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com